Skip to main content
. 2021 Nov 12;9(11):1316. doi: 10.3390/vaccines9111316

Figure 2.

Figure 2

m81 mAb is specific for human IAPP fibrils, but not rat IAPP nor monomeric human IAPP. (A) Purified m81 mAb tested in an ELISA assay with either RNase-Nterm(S-S) (green circle), hIAPP (grey square), or rIAPP (red triangle) coating, with the corresponding area under the curve (AUC). Statistics were performed by one-way ANOVA using Tukey’s multiple comparison test, where the mean of each group was compared to the other groups. *** p < 0.001 and **** p < 0.0001. Data are presented as mean ± SEM. (B) Specificity for rIAPP, hIAPP monomer, hIAPP fibrils, and a negative control amyloidogenic Aβ peptide was tested on a dot blot at 500, 50, and 5 μg/mL. (C) Representative human pancreatic islet from a patient suffering from T2DM. Amyloidogenic aggregates were stained with ThioflavinS dye (ThioS, left panel, green) and purified m81 mAb(m81, middle panel, red). A merge image was created to visualize co-localization (Merge, right panel, yellow). RNase-Nterm(S-S), N terminal peptide with disulfide bridge (S-S); rIAPP, rat IAPP; hIAPP, human IAPP; Aβ, Amyloid beta; ThioS, ThioflavinS; T2DM. Scale bars: 20 μm.